ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2024
Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis.
Emma Hazelwood, Catalina Lopez Manzano, Emma E Vincent, Demetrius Albanes, David Timothy Bishop, Loïc Le Marchand, Cornelia M Ulrich, Ulrike Peters, Gwen Murphy, Niloy Jewel Samadder and 5 more
Abstract read
In one paragraphArticle in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Emma HazelwoodMRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-4888-6037 Catalina Lopez ManzanoPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.ORCID 0009-0009-8883-0167 Emma E VincentMRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-8917-7384 Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-8330-4293 David Timothy BishopLeeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom.ORCID 0000-0002-8752-8785 Cornelia M UlrichHuntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.ORCID 0000-0001-7641-059X Gwen MurphyCancer Screening and Prevention Research Group (CSPRG), Department of Surgery and Cancer, Imperial College London, London, United Kingdom.ORCID 0000-0003-0118-5337 Laura AndersonDepartment of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada.ORCID 0000-0002-6106-5073 Marc J GunterNutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-5472-6761 Neil MurphyNutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-3347-8249 Bethany Van Guelpen *Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden.ORCID 0000-0002-9692-101X Nikos Papadimitriou *Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-8294-7262 Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MTranslational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MSWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2MUSC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8MWOMEN'S HEALTH INITIATIVE - CLINICAL COORDINATING CENTER: TASK AREA B - LONG LIFE STUDY VISIT 2 LIMITED HOME VISIT75N92021D00001 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L. · 2021 to 2025
$52.0MValidity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI RIMM, ERIC B · 1991 to 2009
$41.8MUNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ian Michael Carroll · 1999 to 2026
$31.6MPILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Temitope O. Keku · 1985 to 2026
$30.5MStatistical Methods for Integrative Genomics in CancerP01CA196569 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul Marjoram · 2016 to 2026
$25.5MAgència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) 2014SGR135Agency for Management of University and Research Grants of the Catalan Government 2017SGR723American Cancer Society (ACS)American Institute for Cancer Research (AICR)Bundesministerium für Bildung und Frauen (BMBF) 01KH0404Canadian Cancer Society (CCS)Canadian Institutes of Health Research (CIHR) 112746Cancer Council VictoriaCancerfonden (Swedish Cancer Society) 21 0467 FE 01 HCancerfonden (Swedish Cancer Society) 23 3153 PjCancer Research UK (CRUK) C18281/A29019Cancer Research UK (CRUK) C18281/A30905Centers for Disease Control and Prevention (CDC) NU58DP006333Chonnam National University Hwasun Hospital (CNUHH) HCRI15011-1Damon Runyon Cancer Research Foundation (DRCRF) NCI R01CA136726Danish Cancer Society Research Center (DCRC)Deutsche Krebshilfe (German Cancer Aid)European Cooperation in Science and Technology (COST) BM1206 and CA17118FEDER PI14-613Federación Española de Enfermedades Raras (FEDER) PI08/0024Florida Department of Health (DOH) 09BN-13Food Standards Agency (FSA)Fundación Científica Asociación Española Contra el Cáncer (AECC) GCB13131592CASTGeneralitat de Catalunya (Government of Catalonia) SLT002/16/00398Herzfelder'sche Familienstiftung (Herzfelder Family Foundation)Imperial College London (ICL)Institut National de la Santé et de la Recherche Médicale (Inserm)Instituto de Salud Carlos III (ISCIII)Intramural NIH HHS Z01 CP010200Junta de Castilla y León (JCYL) LE22A10-2Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation) VLL-765961KWF Kankerbestrijding (DCS) UM 2012-Ligue Contre le Cancer (French League Against Cancer)Medical Research Council MC_UU_00032/3Medical Research Council (MRC) 1000143Medical Research Council (MRC) MC_UU_00032/03Ministerio de Economía y Competitividad (MEC) SAF07-64873Mutuelle Générale de l'Education Nationale (MGEN)National Health and Medical Research Council (NHMRC) 509348National Institutes of Health (NIH) HHSN268201700006INational Research Council (NRC)NCATS NIH HHS KL2 TR000421NCI NIH HHS K05 CA152715NCI NIH HHS K05 CA154337NCI NIH HHS P01 CA033619NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA196569NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA042182NCI NIH HHS R01 CA048998NCI NIH HHS R01 CA059045NCI NIH HHS R01 CA060987NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA066635NCI NIH HHS R01 CA067941NCI NIH HHS R01 CA072520NCI NIH HHS R01 CA076366NCI NIH HHS R01 CA081488NCI NIH HHS R01 CA097325NCI NIH HHS R01 CA136726NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA143237NCI NIH HHS R01 CA151993NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA197350NCI NIH HHS R01 CA201407NCI NIH HHS R01 CA207371NCI NIH HHS R01 CA242218NCI NIH HHS R01 CA273198NCI NIH HHS R03 CA153323NCI NIH HHS R35 CA197735NCI NIH HHS R37 CA054281NCI NIH HHS U01 CA067941NCI NIH HHS U01 CA074783NCI NIH HHS U01 CA074794NCI NIH HHS U01 CA086308NCI NIH HHS U01 CA122839NCI NIH HHS U01 CA137088NCI NIH HHS U01 CA152753NCI NIH HHS U01 CA167551NCI NIH HHS U01 CA167552NCI NIH HHS U01 CA206110NCI NIH HHS U10 CA037429NCI NIH HHS U19 CA148107NCI NIH HHS U24 CA074794NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA182883NCI NIH HHS UM1 CA186107NHGRI NIH HHS U01 HG004438NHGRI NIH HHS U01 HG004446NHLBI NIH HHS 75N92021D00001NHLBI NIH HHS 75N92021D00002NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008INHLBI NIH HHS HHSN268201700006CNIA NIH HHS U01 AG018033NIDDK NIH HHS P30 DK034987NIDDK NIH HHS P30 DK056350NIEHS NIH HHS T32 ES013678NIH HHS S10 OD028685Office of Research Infrastructure Programs (ORIP) S10OD028685Ontario Ministry of Research and Innovation (MRI)Pelotoniaplatforma biobancos PT13/0010/0013Region SkåneState of Maryland (Maryland)Stockholm läns landsting (Stockholm County Council)Swedish Cancer FoundationTranscan (Transcan-3) JTC2012-MetaboCCCVetenskapsrådet (VR) VR 2017-00650VicHealth (Victorian Health Promotion Foundation)Victorian Cancer Agency (VCA) MCRF18005Wereld Kanker Onderzoek Fonds (WKOF) IIG_FULL_2021_030WHI NIH HHS 75N92021D00003WHI NIH HHS 75N92021D00004WHI NIH HHS 75N92021D00005World Cancer Research Fund (WCRF) IIG_FULL_2021_030World Health Organization 001Xunta de Galicia (Regional Government of Galicia) PGIDIT07PXIB9101209PRZonMw (Netherlands Organisation for Health Research and Development) 98-10030
6 · The paper itselfAbstract
backgroundEpidemiological and laboratory-based studies have provided conflicting evidence for a role of ghrelin in colorectal cancer development. We conducted two-sample Mendelian randomization (MR) analyses to evaluate evidence for an association of circulating ghrelin and colorectal cancer risk overall and by sex, cancer subsite, and age at diagnosis.
methodsGenetic instruments proxying plasma total ghrelin levels were obtained from a recent genome-wide association study of 54,219 participants. Summary data for colorectal cancer risk were obtained from a recent meta-analysis of several genetic consortia (up to 73,673 cases and 86,854 controls). A two-sample MR approach and several sensitivity analyses were applied.
resultsWe found no evidence for an association of genetically predicted plasma total ghrelin levels and colorectal cancer risk (0.95, 95% confidence interval, 0.81-1.12; R2 of ghrelin genetic instruments: 4.6%), with similarly null results observed when stratified by sex, anatomical subsite, and for early-onset colorectal cancer.
conclusionsOur study suggests that plasma ghrelin levels are unlikely to have a causal relationship with overall, early-onset, and sex- and cancer subsite-stratified colorectal cancer risk. IMPACT: This large-scale analysis adds to the growing body of evidence that plasma total ghrelin levels are not associated with colorectal cancer risk.
Indexed as
Colorectal NeoplasmsGhrelinMendelian Randomization AnalysisAge of OnsetFemaleGenome-Wide Association StudyHumansMalePolymorphism, Single NucleotideRisk FactorsSex FactorsGhrelin
Identifiers
PMID39361354
PMCPMC11609820
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390